Rezpegaldesleukin (or NKTR-358) Starts A Phase-IIΔ Clinical Trial on Honeymooners (RESET T1D)

A new clinical trial is testing Rezpegaldesleukin, also known as NKTR-358, or REZPEG, as a potential treatment to slow or stop T1D in honeymooners. Rezpegaldesleukin is a modified form of interleukin-2 (IL-2), which plays a key role in regulating the immune system. The drug is given by subcutaneous injection, similar to an insulin injection, once every two weeks. It has been studied across nine…